Verastem Oncology announced that its oral inhibitor VS-7375, targeting Kras G12d-mutated metastatic pancreatic cancer, has completed dosing for the first patient in the Target-D 201 phase II registration-directed study.

Verastem Oncology announced that its oral inhibitor VS-7375, targeting Kras G12d-mutated metastatic pancreatic cancer, has completed dosing for the first patient in the Target-D 201 phase II registration-directed study.

老虎证券2026/06/16 20:17

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This pivotal study aims to evaluate the efficacy and safety of the drug, marking a substantial step forward for this innovative therapy toward potential registration and market launch. VS-7375 is a novel Kras G12d (on/off) inhibitor, designed to precisely target this specific gene mutation commonly found in pancreatic cancer.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Verastem Oncology announced that its oral inhibitor VS-7375, targeting Kras G12d-mutated metastatic pancreatic cancer, has completed dosing for the first patient in the Target-D 201 phase II registration-directed study.

You may also like

Crypto prices